project id: TCGA-PRAD; case submitter id: TCGA-2A-A8VV; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.91; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.99; rna integrity number: 8.5; age at index: 52; days to birth: -19065; ethnicity: not hispanic or latino; gender: male; race: not reported; vital status: Alive; year of birth: 1958; age at diagnosis: 19065; ajcc clinical m: M0; ajcc clinical t: T2b; ajcc pathologic n: N0; ajcc pathologic t: T2b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 671.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 3; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2010; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 1155; days to sample procurement: 0; initial weight: 140.0; portion submitter id: TCGA-2A-A8VV-01A-11; percent lymphocyte infiltration: 4.0; percent monocyte infiltration: 1.0; percent necrosis: 3.0; percent neutrophil infiltration: 1.0; percent normal cells: 7.0; percent stromal cells: 45.0; percent tumor cells: 45.0; percent tumor nuclei: 80.0;